Replimune Group Inc. Common Stock (REPL)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I begin with what is knowable. Replimune is a clinical-stage biotech with 465 employees, no revenue, and no reported profit. In fiscal 2026, the year ended 2026-03-31, it lost $313.9 million, or $3.38 per diluted share. That was worse than fiscal 2025's $247.3 million loss and fiscal 2024's $215.8 million loss. More recent filings show fiscal Q1 2027, the quarter ended 2026-06-30, lost $69.8 million, or $0.72 per diluted share, which was smaller than fiscal Q1 2026's $86.7 million loss but still heavy before any product revenue. Trailing free cash flow is negative $280.5 million, and FairStock's FCF yield is -127.2% against a $220.5 million market cap at the 2026-10-13 close. That means cash consumption is enormous relative to market value. Debt-to-equity is 1.06, ROE is -134.29%, and ROCE is -51.30%, while Altman Z-score is -5.72 and Piotroski F-score is 1/9. At $12.11, FairStock's P/E is -3.84 and P/B is 9.61, so earnings and book value offer little conventional support. The FairStock Score is 36/100, and the Lynch category is none because it lost money in each of the last four years. Growth is a hope for RP1, not a proven record. Without revenue, an approved product, or positive cash flow, the margin of safety is speculative. I would demand much more clinical and financial evidence before calling this anything but a high-risk option on future science.

In plain English: Replimune is a healthcare company trying to make new cancer treatments; it does not yet sell products and has no revenue. It has been losing money for years, and the losses are very large. At the 2026-10-13 closing price of $12.11, the stock looks expensive compared with the business's current numbers because there are no profits to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2025-12-31) · fiscal Q2 2026 10-Q (period ended 2025-09-30) · fiscal Q1 2026 10-Q (period ended 2025-06-30) · FY2026 10-K (period ended 2026-03-31) · FY2025 10-K (period ended 2025-03-31) · FY2024 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer